Humira has been a blockbuster drug since its approval in 2002. As Humira goes off-patent, biosimilars are now entering the market, offering more affordable treatment options for patients.
What is Humira?
Humira (adalimumab) is a biologic drug developed and marketed by AbbVie for the treatment of several autoimmune diseases such as rheumatoid arthritis, Crohn's disease, psoriasis etc. It is a monoclonal antibody and works by blocking tumor necrosis factor- ... Read more
